

Jameel Nazir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5197927/publications.pdf>

Version: 2024-02-01

18
papers

819
citations

840776

11
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

697
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. <i>European Urology</i> , 2014, 65, 755-765.	1.9	223
2	Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. <i>European Urology</i> , 2017, 72, 389-399.	1.9	162
3	Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 74, 324-333.	1.9	151
4	Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. <i>BMJ Open</i> , 2018, 8, e021889.	1.9	81
5	Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database. <i>International Journal of Clinical Practice</i> , 2017, 71, e12996.	1.7	29
6	Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom. <i>Value in Health</i> , 2015, 18, 783-790.	0.3	28
7	Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 200.	2.4	24
8	Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom. <i>Clinical Drug Investigation</i> , 2015, 35, 83-93.	2.2	22
9	Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data. <i>Current Medical Research and Opinion</i> , 2015, 31, 43-50.	1.9	20
10	Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis. <i>Neurourology and Urodynamics</i> , 2018, 37, 986-996.	1.5	12
11	A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain. <i>BMC Urology</i> , 2018, 18, 76.	1.4	12
12	Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK. <i>PharmacoEconomics - Open</i> , 2017, 1, 25-36.	1.8	11
13	Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. <i>Journal of Medical Economics</i> , 2017, 20, 614-622.	2.1	10
14	Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. <i>Canadian Urological Association Journal</i> , 2017, 11, 123.	0.6	10
15	Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service. <i>Journal of Medical Economics</i> , 2015, 18, 390-397.	2.1	8
16	Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>BMC Urology</i> , 2015, 15, 41.	1.4	6
17	A critical appraisal of the principal guidelines for neurogenic lower urinary tract dysfunction using the AGREE II instrument. <i>Neurourology and Urodynamics</i> , 2018, 37, 2945-2950.	1.5	6
18	Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. <i>Journal of Market Access & Health Policy</i> , 2018, 6, 1438721.	1.5	4